What "Compounded" Actually Means in Medicine (And What It Doesn't)

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

A patient sat across from me a few weeks ago holding up her phone. She'd screenshotted an ad. "It says compounded," she told me. "What does that actually mean? Is that the cheap version, or the better version?"

Neither, is the honest answer. And that's the problem. "Compounded" isn't a quality grade. It isn't a tier. It doesn't mean natural, advanced, customized-just-for-you, or any of the other things wellness marketing has quietly attached to it over the past decade. The word describes how a preparation was made and who made it. That's close to all it tells you.

I'm Dr. Farhan Abdullah. I'm a board-certified internal medicine physician, I still round on hospitalized patients in Dallas every month, and I'm the medical director at Magnolia Functional Wellness in Southlake. Untangling this particular confusion takes up more of my consultation time than almost any other topic. So let's take the word apart properly, because a patient who understands it makes better decisions than one who doesn't.

Compounding Describes a Process, Not a Standard

Pharmacy compounding is old. It predates the modern pharmaceutical industry by centuries. In its traditional form, it's a licensed pharmacist preparing a medication for one specific patient, based on one specific prescription, because the commercially available product won't work for that person.

The classic reasons are genuinely good ones. A three-year-old can't swallow a tablet, so a pharmacist turns it into a suspension. An adult reacts to a dye or a preservative in the commercial formulation, so a pharmacist prepares it without that ingredient. A patient needs a strength that simply isn't manufactured. A product gets discontinued and a small number of people still depend on it. In each of those cases compounding is solving a real clinical problem that mass manufacturing can't solve.

Here's what it isn't. When the U.S. Food and Drug Administration approves a drug, the approval attaches to a specific product, made by a specific manufacturer, using a specific validated process, studied in specific clinical trials, with specific labeling. That whole package is what got reviewed. A compounded preparation has not gone through any of that. It hasn't been evaluated by the FDA for safety. It hasn't been evaluated for effectiveness. Its manufacturing process hasn't been reviewed or approved.

That's not a rhetorical jab at compounding pharmacies, many of which are careful, well-run operations staffed by people who take their work seriously. It's a description of a regulatory boundary that exists whether anyone likes it or not. Ozempic and Wegovy are FDA-approved products. Mounjaro and Zepbound are FDA-approved products. Semaglutide and tirzepatide are the drug substances those products are built around. A compounded preparation is a different thing from an approved product, and no amount of confident marketing collapses that distinction.

What I tell my patients is this: the word "compounded" answers a manufacturing question. It doesn't answer the two questions you actually care about, which are whether this is the right treatment for you and whether what's in the vial is what the label says.

503A and 503B Are Not the Same Animal

If you're going to learn one piece of regulatory vocabulary, learn this one. It's the difference most patients have never heard of, and it matters more than almost anything else on a clinic's website.

Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies. These prepare medications against individual patient prescriptions. Oversight comes primarily from state boards of pharmacy. The FDA has authority here, but day-to-day inspection and licensing is largely a state function, and standards vary meaningfully from state to state.

Section 503B covers what are called outsourcing facilities. This category didn't exist until Congress created it through the Drug Quality and Security Act in 2013, and the reason it exists is grim. In 2012, a Massachusetts compounding operation shipped contaminated steroid injections across the country. The resulting fungal meningitis outbreak sickened hundreds of people and killed dozens. Congress responded by building a category for larger-scale compounders: 503B facilities register with the FDA, are subject to current good manufacturing practice requirements, and get inspected by the agency.

That's real oversight, and it's a meaningful improvement over what came before. But read the next sentence carefully, because this is where marketing copy tends to blur things. FDA registration and inspection of a facility is not FDA approval of a product. Those are two different determinations answering two different questions. A 503B facility can be registered, inspected, and operating properly, and the preparations coming out of it are still not FDA-approved drugs. They were never submitted for approval. Nobody claimed they were.

So when you read that something came from an FDA-registered facility, the accurate translation is "the facility is on a list the FDA maintains and inspects." That's worth something. It is not the sentence a lot of readers think they just read.

What the Published Evidence Says

This is where I'd rather point at data than at opinion.

A frequently cited 2013 review in Drugs in R&D by Gudeman and colleagues laid out the structural issues plainly. Compounded preparations are exempt from the good manufacturing practice regulations that govern approved drugs. Testing to confirm product quality is inconsistent. Compounded products don't carry standardized labeling or prescribing information. And compounding pharmacies historically weren't required to report adverse events to the FDA, which manufacturers of approved drugs must do. The authors also noted something worth sitting with: independent testing by the FDA and state agencies has repeatedly found compounded preparations failing to meet specifications at a considerably higher rate than approved drugs.

In the hormone world, the American College of Obstetricians and Gynecologists took a clear position in its 2023 Clinical Consensus No. 6, published in Obstetrics & Gynecology. ACOG observed that compounding pharmacies often deploy "bioidentical" as a marketing term implying these preparations are more natural, safer, or more effective than approved menopausal hormone therapies, and that the evidence supporting those marketing claims is lacking. Their recommendation was that compounded bioidentical hormone therapy shouldn't be prescribed routinely when approved formulations exist, and that if a patient does want it, the clinician's job is to educate her honestly about the absence of FDA approval and the risks specific to compounding.

More recently, McCall and colleagues published a pharmacovigilance analysis in Expert Opinion on Drug Safety examining the FDA Adverse Event Reporting System from 2018 through 2024. Out of roughly 81,000 reports involving GLP-1 receptor agonists, 707 involved compounded products. The compounded reports carried higher reporting odds for several adverse events, and notably higher reporting odds for preparation errors, prescribing errors, contamination, and compounding or manufacturing problems. Reported hospitalization odds were higher too.

I want to be careful about what that study does and doesn't establish. It's a disproportionality analysis of a voluntary reporting database. It cannot demonstrate cause and effect, and the authors say so directly. Reporting patterns are influenced by publicity, and compounded GLP-1 products got a great deal of publicity during the shortage years. But the error and contamination signals in particular are exactly the categories you'd expect to move if preparation quality varies, and they're consistent with what Gudeman described a decade earlier. When two independent lines of evidence point the same direction, I pay attention.

Where Compounding Genuinely Belongs

None of this makes compounding illegitimate. I want to be clear about that, because the pendulum swings both ways and I've watched patients get talked out of a preparation they genuinely needed.

Compounding earns its place when there's a real clinical gap. A documented allergy or intolerance to something in the commercial formulation. A dose that isn't manufactured and can't be reached by splitting or combining what is. A route or form the patient can't manage otherwise. A product that's been discontinued while a handful of people still depend on it. In those situations a compounding pharmacy is doing precisely the job the category was designed for, and the alternative isn't a better product, it's no product.

Where I get uneasy is when compounding stops being about a clinical gap and starts being about convenience, marketing, or margin. The FDA's rules exist partly to prevent compounders from essentially producing copies of commercially available approved drugs, and there's a reason for that boundary. When a preparation is chosen because it's easier to source or because it lets a clinic advertise something distinctive, rather than because a specific patient in front of a specific clinician needs it, the clinical logic has quietly inverted.

At Magnolia, this shapes how we run peptide medication therapy and how we structure our physician-supervised GLP-1 weight loss program. The starting question is always which treatment the evidence supports for this person, followed by what documentation exists for whatever we're actually putting in their body. I'd rather have a slightly awkward conversation about why we're doing something a particular way than hand someone a vial and a shrug.

The Questions I'd Want You Asking

If you're evaluating any clinic, here or anywhere else, these are the questions I'd want a member of my own family to ask. A good clinic will answer them without getting defensive. That reaction is itself part of the information.

• Is what you're recommending an FDA-approved product, or a compounded preparation? Say which.
• If it's compounded, which pharmacy, and is it a 503A pharmacy or a 503B outsourcing facility?
• Why compounded rather than an approved product? What's the specific clinical reason in my case?
• What testing does that pharmacy perform on its preparations, and can I see documentation?
• Who is monitoring me, how often, and what specifically are you watching for?
• What happens if I have a reaction? Who do I call at 9pm on a Saturday?

That last one sounds mundane next to the regulatory questions. It isn't. A clinic's answer to "who picks up the phone" tells you how it thinks about the whole relationship.

Here's what I'd take away from all of this. "Compounded" is a neutral, technical word that has been doing an enormous amount of unearned persuasive work in wellness advertising. It's not a synonym for premium and it's not a synonym for shortcut. It means a pharmacist prepared something, under a specific set of rules that are genuinely different from the ones governing approved drugs, and the burden of judgment shifts substantially onto your prescribing clinician as a result. Knowing that doesn't make you cynical. It makes you a harder person to sell to, which in this corner of medicine is a real form of protection.

If you're somewhere in Southlake or the broader DFW area trying to sort out what you've been offered and whether it makes sense, bring the ad, bring the label, bring the screenshots. I've yet to meet a patient who asked too many questions. At Magnolia Functional Wellness, that conversation is the appointment, not an interruption of it.